GALA
Based on 1 Customer Validation
GALA is a pH-responsive amphipathic peptide consisting of 30 amino acids, which acts as a lung endothelium-targeting ligand. GALA undergoes a conformational transition from random coil to α-helix in an acidic environment at pH 5.0, thereby inducing endosomal membrane destabilization and fusion. GALA-modified liposomes traverse lung endothelial cells via clathrin-dependent endocytosis and transcytosis, and specifically accumulate in the lungs after intravenous injection. GALA significantly promotes the cytosolic release of cargos carried by exosomes, plasmids and liposomes, effectively enhances gene transfection efficiency, and drives gene knockdown of functional macromolecules (such as siRNA) in alveolar epithelial cells (with no significant cytotoxicity at effective concentrations). GALA serves as a critical tool for studies on lung cancer metastasis (e.g., melanoma lung metastasis) and lung-targeted drug delivery systems.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.01%
- CAS 番号: 107658-43-5
- 分子式: C136H215N33O45
- 分子量:3032.36
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
生物活性
製品説明
体外実験
GALA/Chol-LPs (11-55 nmole lipids; 2-3 h) are mainly internalized by human lung microvascular endothelial cells (HMVEC-L) via the clathrin-mediated endocytosis pathway. After 3 h of incubation, 14 μM Chlorpromazine (HY-12708) inhibits its uptake by 52%[1].
When combined with exosomes not expressing CD63-GFP and Lipofectamine LTX, GALA peptide (0.5-2 μM; 37 °C; 6 h) exhibits enhanced cellular uptake efficiency and cytosolic distribution levels in HeLa cells, with 2 μM GALA increasing the cellular uptake level by approximately 12-fold[2].
When used in combination with Lipofectamine LTX, GALA peptide (2-10 μM; 37 °C; 6 h) increases the cellular uptake of CD63-GFP-expressing exosomes in HeLa cells by approximately 1.5-fold at a concentration of 2 μM, while 10 μM GALA peptide reduces the uptake efficiency[2].
When used in combination with Texas red (HY-101878)-labeled dextran-encapsulated exosomes and Lipofectamine LTX, GALA peptide (0.5-2 μM; 37 °C; 6 h) drives efficient cytosolic release of dextran in HeLa cells, with 2 μM GALA inducing cytosolic dextran signals in approximately 60% of cells[2].
Co-treatment with the GALA peptide (2 μM; 37 °C; 24 h), saporin-loaded exosomes and Lipofectamine LTX induces approximately 98% death of HeLa cells, and exerts potent cytotoxicity by enhancing the cytoplasmic delivery of saporin[2].
GALA (0.1-5.0 μM; 12-48 h) enhances Lipofectin-mediated luciferase transfection efficiency in COS-7 cells in a concentration-dependent manner. Specifically, treatment with 0.1 μM GALA for 48 h increases the transfection efficiency by 5-fold, and GALA enhances the transfection efficiency by approximately 3.5-fold at all tested time points (12, 24, 48 h)[3].
GALA (0.1-5.0 μM; 48 h) enhances the luciferase transfection efficiency mediated by Lipofectamine 2000 in COS-7 cells, with a 2-fold increase in transfection efficiency observed after treatment with 0.1 μM GALA for 48 h[3].
GALA (0.1 μM; 5 h) does not alter the cellular localization of rhodamine-labeled plasmid DNA in Lipofectin-transfected COS-7 cells, but it colocalizes with the plasmid in vesicles and exhibits diffuse cytoplasmic staining[3].
GALA (0.1 μM; 5 h) reduces cellular uptake of rhodamine-labeled plasmid DNA in COS-7 cells transfected with cationic liposomes, with the greatest reduction (approximately 19%) observed when Lipofectin is used[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HeLa cells
-
Concentration:2 μM
-
Incubation Time:24 h (37 °C)
-
Result:Induced significant morphological changes in HeLa cells and approximately 98% cell death, as measured by WST-1 assay, when co-treated with Lipofectamine LTX and saporin-encapsulated exosomes.
-
Cell Line:COS-7 simian kidney cells
-
Concentration:0.1 μM (full 48 h total incubation)
-
Incubation Time:48 h (total incubation)
-
Result:Did not cause a substantial decrease in cell viability in Lipofectin-transfected cells, despite increasing transfection efficiency 5-fold. Allowed reduced Lipofectamine 2000 doses with diminished cytotoxicity relative to the full liposome dose control while maintaining high transfection efficiency.
体内実験
GALA/Chol-MEND and GALA/PEG2000-MEND (1.5 mg siRNA/kg; i.v.; single dose) achieve significant gene silencing in mouse type I alveolar epithelial cells, reducing podoplanin mRNA expression by 29% and 24%, respectively[1].
GALA/Chol-MEND (2 mg AuNPs/kg; i.v.; single dose) crosses the mouse lung air-blood barrier, delivering gold nanoparticles to lung endothelial cells, alveolar epithelial cells, and alveolar macrophages[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice (male, 6-8 weeks old, 20-25 g)[1]
-
Dosage:26.4 nmol lipids/kg
-
Administration:i.v.; single dose
-
Result:Achieved uptake in >70% of lung endothelial cells (CD31(+)/CD45(-)).
Achieved uptake in ~30-35% of type I alveolar epithelial cells (Podoplanin(+)/EpCAM(+)/CD31(-)/CD45(-)).
Exhibited highest lung accumulation with GALA/PEG5000-LPs.
Showed highest geometric mean fluorescence intensity in type I alveolar epithelial cells with GALA/PEG2000-LPs.
Observed extravasation from lung blood vessels, with maximum extravasation for GALA/PEG5000-LPs.
化学情報
-
CAS 番号 107658-43-5
-
性状 Solid
-
分子量 3032.36
-
分子式 C136H215N33O45
-
Color White to off-white
-
配列
Trp-Glu-Ala-Ala-Leu-Ala-Glu-Ala-Leu-Ala-Glu-Ala-Leu-Ala-Glu-His-Leu-Ala-Glu-Ala-Leu-Ala-Glu-Ala-Leu-Glu-Ala-Leu-Ala-Ala
-
シーケンスの短縮
WEAALAEALAEALAEHLAEALAEALEALAA
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
体外:
DMSO : 50 mg/mL (16.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 14.29 mg/mL (4.71 mM; adjust pH to 9 with 1 M NaOH)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
RNA interference technology
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing gene transcription or activating RNA degradation. This mechanism was discovered in plants in 1998 by Andrew Fire and Craig Mello. Today, this phenomenon can be observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
純度とドキュメンテーション
-
データシート (287 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Santiwarangkool S, et al. A study of the endocytosis mechanism and transendothelial activity of lung-targeted GALA-modified liposomes. J Control Release. 2019;307:55-63. [Content Brief]
[2]. Nakase I, et al. Combined treatment with a pH-sensitive fusogenic peptide and cationic lipids achieves enhanced cytosolic delivery of exosomes. Sci Rep. 2015;5:10112. Published 2015 May 26. [Content Brief]
[3]. Futaki S, et al. Unique features of a pH-sensitive fusogenic peptide that improves the transfection efficiency of cationic liposomes. J Gene Med. 2005;7(11):1450-1458. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 0.3298 mL | 1.6489 mL | 3.2978 mL | 8.2444 mL |
| DMSO | 5 mM | 0.0660 mL | 0.3298 mL | 0.6596 mL | 1.6489 mL |
| 10 mM | 0.0330 mL | 0.1649 mL | 0.3298 mL | 0.8244 mL | |
| 15 mM | 0.0220 mL | 0.1099 mL | 0.2199 mL | 0.5496 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.